Anti-CD8 monoclonal antibody - CytoDyn

Drug Profile

Anti-CD8 monoclonal antibody - CytoDyn

Alternative Names: Cytolin

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator CytoDyn
  • Class Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action CD11a antigen modulators; CD8-positive T-lymphocyte inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections in USA (IV, Infusion)
  • 21 Jan 2010 Phase-I clinical trials in HIV infections in USA (IV)
  • 09 Oct 2009 CytoDyn transfers research of Cytolin® to Massachusetts General Hospital
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top